• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.双效头孢菌素Ro 23-9424的体外活性与其他抗生素活性的比较
Antimicrob Agents Chemother. 1990 Feb;34(2):189-95. doi: 10.1128/AAC.34.2.189.
2
In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.双效抗菌剂Ro 23-9424对癌症患者分离出的细菌的体外活性与其他药剂的比较。
Antimicrob Agents Chemother. 1992 Apr;36(4):879-82. doi: 10.1128/AAC.36.4.879.
3
Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.新型酯联氟罗沙星和去乙酰头孢噻肟共聚物Ro 23-9424的抗菌活性
Antimicrob Agents Chemother. 1989 Jun;33(6):944-50. doi: 10.1128/AAC.33.6.944.
4
In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.双效抗菌剂Ro 23-9424及对照剂的体外活性
Antimicrob Agents Chemother. 1989 Jul;33(7):1072-7. doi: 10.1128/AAC.33.7.1072.
5
In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.与头孢噻肟和氟罗沙星相比,双效抗菌药物Ro 23-9424的体内评估
Chemotherapy. 1990;36(2):109-16. doi: 10.1159/000238756.
6
Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
Diagn Microbiol Infect Dis. 1994 Jan;18(1):61-8. doi: 10.1016/0732-8893(94)90135-x.
7
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].[1996年抗微生物药物对尿路感染患者分离出的病原体的活性比较研究。I. 敏感性分布]
Jpn J Antibiot. 1998 Feb;51(2):69-111.
8
Mode of action of the dual-action cephalosporin Ro 23-9424.双效头孢菌素Ro 23-9424的作用模式
Antimicrob Agents Chemother. 1989 Jul;33(7):1067-71. doi: 10.1128/AAC.33.7.1067.
9
In vitro activity of Ro 23-9424, a dual-acting cephalosporin-quinolone antimicrobial agent.
J Clin Pharmacol. 1993 Oct;33(10):923-8. doi: 10.1002/j.1552-4604.1993.tb01923.x.
10
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.注射用头孢菌素FK-037的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1993 Mar;37(3):566-73. doi: 10.1128/AAC.37.3.566.

引用本文的文献

1
The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group.《Odd Couple(s): 多药效团β-内酰胺类抗生素概述》
Int J Mol Sci. 2021 Jan 9;22(2):617. doi: 10.3390/ijms22020617.
2
Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating .含双药效团的吡啶硫酮头孢菌素对复制型和非复制型均有杀灭作用。
ACS Infect Dis. 2019 Aug 9;5(8):1433-1445. doi: 10.1021/acsinfecdis.9b00112. Epub 2019 Jun 11.
3
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?抗生素杂合体:下一代针对革兰氏阴性病原体的药物和佐剂?
Clin Microbiol Rev. 2018 Mar 14;31(2). doi: 10.1128/CMR.00077-17. Print 2018 Apr.
4
A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.一种混合药物通过规避多重抗生素耐药途径的作用来限制耐药性。
Mol Biol Evol. 2016 Feb;33(2):492-500. doi: 10.1093/molbev/msv243. Epub 2015 Nov 3.
5
Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.头孢噻肟。对其抗菌活性和药代动力学特性的重新评估,以及对其每日两次给药治疗轻至中度感染时的治疗效果的综述。
Drugs. 1997 Mar;53(3):483-510. doi: 10.2165/00003495-199753030-00009.
6
Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats.大鼠脑室内微量注射后某些β-内酰胺类抗生素的结构与惊厥特性之间的关系
Antimicrob Agents Chemother. 1995 Jan;39(1):232-7. doi: 10.1128/AAC.39.1.232.
7
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.氟罗沙星。对其在各种感染中的药理学及治疗效果的综述。
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
8
Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.双效头孢菌素Ro 23 - 9424在动物体内的药代动力学
Antimicrob Agents Chemother. 1990 Oct;34(10):1895-900. doi: 10.1128/AAC.34.10.1895.
9
In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.双效抗菌剂Ro 23-9424对癌症患者分离出的细菌的体外活性与其他药剂的比较。
Antimicrob Agents Chemother. 1992 Apr;36(4):879-82. doi: 10.1128/AAC.36.4.879.
10
In vitro activity of Ro 23-9424 against clinical isolates of Legionella species.Ro 23-9424对嗜肺军团菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1992 Nov;36(11):2559-61. doi: 10.1128/AAC.36.11.2559.

本文引用的文献

1
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.新型氟化4-喹诺酮Ro 23-6240的体外活性
Antimicrob Agents Chemother. 1986 Apr;29(4):675-80. doi: 10.1128/AAC.29.4.675.
2
In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.双效抗菌剂Ro 23-9424及对照剂的体外活性
Antimicrob Agents Chemother. 1989 Jul;33(7):1072-7. doi: 10.1128/AAC.33.7.1072.
3
Mode of action of the dual-action cephalosporin Ro 23-9424.双效头孢菌素Ro 23-9424的作用模式
Antimicrob Agents Chemother. 1989 Jul;33(7):1067-71. doi: 10.1128/AAC.33.7.1067.
4
Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.新型酯联氟罗沙星和去乙酰头孢噻肟共聚物Ro 23-9424的抗菌活性
Antimicrob Agents Chemother. 1989 Jun;33(6):944-50. doi: 10.1128/AAC.33.6.944.
5
A new cephalosporin with a dual mode of action.一种具有双重作用模式的新型头孢菌素。
Antimicrob Agents Chemother. 1976 Aug;10(2):245-8. doi: 10.1128/AAC.10.2.245.

双效头孢菌素Ro 23-9424的体外活性与其他抗生素活性的比较

In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.

作者信息

Gu J W, Neu H C

机构信息

Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.

出版信息

Antimicrob Agents Chemother. 1990 Feb;34(2):189-95. doi: 10.1128/AAC.34.2.189.

DOI:10.1128/AAC.34.2.189
PMID:2327765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC171554/
Abstract

The in vitro activity of Ro 23-9424, which is desacetyl-cefotaxime linked to fleroxacin, was compared with the activities of cefotaxime, desacetyl-cefotaxime, fleroxacin, ofloxacin, and ciprofloxacin. It inhibited the majority of members of the family Enterobacteriaceae, except for some Serratia marcescens, Citrobacter freundii, and Enterobacter cloacae strains, at less than or equal to 0.25 microgram/ml and had an MIC for 90% of strains tested (MIC90) of 8 micrograms/ml against Pseudomonas aeruginosa. Most group A, B, C, and G streptococci and Streptococcus pneumoniae were inhibited at less than or equal to 0.25 microgram/ml. Ninety percent of the staphylococci were inhibited at less than or equal to 4 micrograms/ml, except for some methicillin-resistant Staphylococcus aureus isolates. The MIC90S of Ro 23-9424 for Enterococcus faecalis and Listeria monocytogenes were greater than or equal to 16 micrograms/ml. Ninety percent of Clostridium perfringens isolates were inhibited by less than or equal to 2 micrograms/ml, whereas Bacteroides fragilis had an MIC90 of 32 micrograms/ml. There was a minimal inoculum size effect. The MICs and MBCs were either identical or within a twofold dilution. The MICs of Ro 23-9424 for Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, Citrobacter freundii, Pseudomonas aeruginosa, and Staphylococcus aureus increased 16- to 128-fold after 2 weeks of transfer in the presence of Ro 23-9424, showing that the presence of two agents does not prevent resistance.

摘要

将去乙酰头孢噻肟与氟罗沙星相连的Ro 23-9424的体外活性,与头孢噻肟、去乙酰头孢噻肟、氟罗沙星、氧氟沙星和环丙沙星的活性进行了比较。它能抑制大多数肠杆菌科成员,除了一些粘质沙雷氏菌、弗氏柠檬酸杆菌和阴沟肠杆菌菌株,其抑制浓度小于或等于0.25微克/毫升,对铜绿假单胞菌的90%受试菌株的最低抑菌浓度(MIC90)为8微克/毫升。大多数A、B、C和G组链球菌以及肺炎链球菌在小于或等于0.25微克/毫升时被抑制。90%的葡萄球菌在小于或等于4微克/毫升时被抑制,除了一些耐甲氧西林金黄色葡萄球菌分离株。Ro 23-9424对粪肠球菌和单核细胞增生李斯特菌的MIC90大于或等于16微克/毫升。90%的产气荚膜梭菌分离株在小于或等于2微克/毫升时被抑制,而脆弱拟杆菌的MIC90为32微克/毫升。接种量效应极小。MIC和MBC要么相同,要么在两倍稀释范围内。在Ro 23-9424存在的情况下传代2周后,Ro 23-9424对大肠杆菌、肺炎克雷伯菌、粘质沙雷氏菌、阴沟肠杆菌、弗氏柠檬酸杆菌、铜绿假单胞菌和金黄色葡萄球菌的MIC增加了16至128倍,表明两种药物同时存在并不能阻止耐药性产生。